zynerba-pipeline-10-16 - Zynerba
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals receives FDA approval for cannabinoid therapies
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
Zygel - Zynerba
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Zygel's anticipated impact on underserved fragile X syndrome market
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/YST6UFBNEVBAXNOUKDYSHHF4AM.PNG "Synthetic CBD from Main Line biotech gets fast track status from FDA")
Synthetic CBD from Main Line biotech gets fast track status from FDA
FDA urged to approve Sarepta DMD drug by dozens of medical experts - STAT
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Form 8-K for Zynerba Pharmaceuticals INC filed 08/09/2022
